WO2009127154A1 - A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs - Google Patents
A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs Download PDFInfo
- Publication number
- WO2009127154A1 WO2009127154A1 PCT/CN2009/071310 CN2009071310W WO2009127154A1 WO 2009127154 A1 WO2009127154 A1 WO 2009127154A1 CN 2009071310 W CN2009071310 W CN 2009071310W WO 2009127154 A1 WO2009127154 A1 WO 2009127154A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hrv
- seq
- sequence
- sample
- nucleotide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 241000430519 Human rhinovirus sp. Species 0.000 title abstract description 39
- 238000012408 PCR amplification Methods 0.000 claims abstract description 8
- 239000000523 sample Substances 0.000 claims description 46
- 239000002773 nucleotide Substances 0.000 claims description 42
- 125000003729 nucleotide group Chemical group 0.000 claims description 42
- 241000709661 Enterovirus Species 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 150000007523 nucleic acids Chemical group 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 108010076039 Polyproteins Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 abstract description 7
- 230000002068 genetic effect Effects 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 16
- 206010011224 Cough Diseases 0.000 description 13
- 208000037656 Respiratory Sounds Diseases 0.000 description 11
- 206010036790 Productive cough Diseases 0.000 description 9
- 208000024794 sputum Diseases 0.000 description 9
- 210000003802 sputum Anatomy 0.000 description 9
- 201000004813 Bronchopneumonia Diseases 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010037833 rales Diseases 0.000 description 7
- 230000000241 respiratory effect Effects 0.000 description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 241001207270 Human enterovirus Species 0.000 description 4
- 206010039109 Rhonchi Diseases 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241001139982 Rhinovirus C Species 0.000 description 3
- 101150093578 VP2 gene Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000013081 phylogenetic analysis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005518 electrochemistry Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150070366 2C gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000124740 Bocaparvovirus Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241001466951 Coxsackievirus A2 Species 0.000 description 1
- 241001669084 Coxsackievirus A6 Species 0.000 description 1
- 241001635223 Coxsackievirus B2 Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000204855 Echovirus E1 Species 0.000 description 1
- 241000709638 Echovirus E6 Species 0.000 description 1
- 241000146324 Enterovirus D68 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241000484121 Human parvovirus Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 241000709704 Human poliovirus 2 Species 0.000 description 1
- 241000829106 Human polyomavirus 3 Species 0.000 description 1
- 241000073293 Human rhinovirus QPM Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101150036700 VP3 gene Proteins 0.000 description 1
- 241000379754 WU Polyomavirus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention generally relates to the identification and detection of human rhino viruses. More particularly, the present invention relates to the characterization of a new strain of human rhinovirus of genetic group C (HRV-C) as well as methods and kits for detecting the presence of HRV-C, for instance, by PCR amplification.
- HRV-C genetic group C
- HRVs Human rhinoviruses
- Rhinoviruses are small RNA, non-enveloped, viruses belonging to the family picornaviridae . Until now, over 100 serotypes of Rhinoviruses have been identified by specific antisera in a collaborative program supported by the World Health Organization (WHO). Rhinoviruses are divided into major (90%) and minor (10%) groups, according to their cellular receptor usage. An alternative classification, dividing the viruses into group A and B, based on sensitivity to antiviral compounds and correlating with sequence similarities and pathogenicity, has also been proposed ⁇ .
- WHO World Health Organization
- Kistler et al ⁇ used virochip to test samples from recruited adults who had cold symptoms from the fall of 2001 to December of 2004. They found 5 divergent HRVs named as HRVX', which possessed slightly more sequence similarity to HRV-A than to HRV-B reference serotypes. None of the divergent HRVX' isolates were culturable.
- Lee et al ⁇ used Respiratory Multicode Assay to analyze nasal lavage samples of infants. They found 5 distinct strains and proposed that they represent a new HRV genetic group (HRV-C). None of the samples containing the new HRV strains produced cytopathic effect (CPE) in standard WI-38 or MRC-5 cell cultures used for the detection and isolation of HRV.
- CPE cytopathic effect
- the present invention is based on the discovery of a new Rhinovirus strain of HRV-C, named BCHO 19, which is believed to be associated with severe respiratory illness.
- BCHO 19 The genomic sequence of BCHO 19 is set out in Figure 1 and SEQ ID NO: 1. The organization of the genome of BCHO 19 is depicted in Figure 2.
- the present invention relates to an isolated HRV-C Rhinovirus having a RNA genome, said genome comprising a polynucleotide sequence selected from the group consisting of:
- the invention also relates to nucleic acid sequences of said virus as well as the use of the above polynucleotide or fragments thereof in designing primers or probes for detecting HRV-C Rhinovirus in a sample.
- the present invention also concerns nucleic fragments comprising or consisting of at least 50 consecutive nucleotides, preferably at least 100, 150 or 200 consecutive nucleotides, belonging to a nucleotide sequence starting at nucleotide 627 and ending at nucleotide 7064 of SEQ ID NO: 1, or belonging to a nucleotide sequence which exhibits at least 85% identity, preferably at least 90 or 95% identity with the nucleotide sequence starting at nucleotide 627 and ending at nucleotide 7064 of SEQ ID NO: 1 or their complementary sequences; and especially the following fragments respectively identified in SEQ ID NO: 21 (VP4 nt 627-827 inclusive), SEQ ID NO: 22 (VP2 nt 828-1613 inclusive) and SEQ ID NO: 23 (PCR product nt 556-886 inclusive) and the variants which exhibit at least 85% identity, preferably at least 90 or 95% identity, respectively or their complementary sequences.
- the present invention provides a pair of primers for amplifying a strain of HRV-C in a sample by PCR amplification, wherein at least one primer comprises a nucleotide sequence which consists of 18 to 30 consecutive nucleotides, especially 18 to 25 consecutive nucleotides, within the region from about nucleotide 556 to about nucleotide 886 of SEQ ID NO: 1.
- the pair of primers comprises a forward primer 556F as set out in SEQ ID NO: 6 and a reverse primer 886R as set out in SEQ ID NO: 7.
- the present invention provides a kit for PCR amplifying a strain of HRV-C in a sample comprising at least one primer pair of the present invention as mentioned above.
- the present invention provides a method for detecting the presence of a strain of HRV-C in a sample, comprising the steps of:
- the sample is selected from the group consisting of human oral and nasal samples (obtained from nasal lavage, nasopharyngeal aspirate, bronchial lavage, sputum, oral and nasal swabs) and viral culture supernatants.
- nucleotide sequences listed as SEQ ID Nos: 1, 21, 22 and 23 correspond to cDNA obtained from the reverse transcription of genomic RNA.
- the invention concerns:
- a polynucleotide sequence selected from the group consisting of: (i) a sequence identified as SEQ ID NO: 1, (ii) a sequence which exhibits at least 75% identity with SEQ ID NO: 1, and (iii) a complementary sequence of a sequence identified in (i) or (ii); or
- nucleic fragment of a polynucleotide the nucleotide sequence of which is defined above in (i), (ii) or (iii); or
- polypeptide the amino acid sequence of which comprises or consists of at least 15 consecutive amino acids, preferably of at least 20 consecutive amino acids, advantageously of at least 30 consecutive amino acids of a protein as defined above in (a);
- a method for detecting the presence of a strain of HRV-C in a sample comprising the steps of contacting the sample with a protein as defined above in (a) or with a polypeptide as defined above in (b) and detecting the presence of an immune complex formed between the protein or polypeptide and anti-HRV-C antibodies, for example by immuno-enzymatic methods including colorimetric, fluorescent, luminescent or electrochemistry detection such as Western Blot, sandwich immunoassay and competition technology; the sample being preferably a human sample selected from the group consisting of blood, plasma and serum;
- a method for detecting the presence of a strain of HRV-C in a sample comprising the steps of contacting the sample with at least one anti-HRV-C antibody having a specificity against an epitope of a HRV-C protein of the strain and detecting the presence of an immune complex of antibody/HRV-C protein, for example by immuno-enzymatic methods including colorimetric, fluorescent, luminescent or electrochemistry detection such as Western Blot, sandwich immunoassay and competition technology; the sample being preferably selected from the group consisting of human oral and nasal samples (obtained from nasal lavage, nasopharyngeal aspirate, bronchial lavage, sputum, oral and nasal swabs) and viral culture supernatants;
- kits for the diagnosis of a strain of HRV-C characterized in that it comprises at least one protein or at least one polypeptide as defined above in (a) or (b);
- Proteins and polypeptides can be produced by recombinant technology or chemical synthesis.
- Antibodies can be polyclonal antibodies, monoclonal antibodies, recombinant antibodies or fragments thereof, such as Fab, Fab', Fab'2, scFv, Fv.
- FIG. 1 set out the genomic sequence of BCHO 19.
- Figure 2 depicts the genomic organization of BCHO 19 (panel A) and positions of the 3 different clones initially obtained by random PCR (panel B).
- Figure 3 shows the results of phylogenetic analysis of HRVs: bootstrapped neighbor- joining tree was constructed based on full-length nucleotide sequence of all known HRVs and some HEVs.
- Figure 4 shows the PCR products obtained by using primers targeting protein coding regions of BCHO 19. The PCR products were separated on agarose gel.
- the present invention is based on the discovery of a new Rhinovirus strain, named BCHO 19, which is believed to be associated with severe respiratory illness.
- BCHO 19 The full genomic sequence of BCHO 19 is set out in Figure 1 and SEQ ID NO: 1. Genomic characterization showed that the full genome of BCHO 19 spans 7121nt, including a 5'-UTR (626nt), a polyprotein coding sequence (6438nt), a 3'-UTR (38nt), and a polyA tail (Fig. 2).
- the organization of the coding region of the precursor polyprotein in BCHO 19 is same as that in all the known HRVs, which has a highly conserved translation initiation site (encoding MGAQVS) and regions corresponding to the capsid genes VP4, VP2, VP3, VPl and non-structural genes 2A, 2B, 2C, 3A, 3B, 3C and 3D.
- VPl is the major protein to form the canyon and the drug-binding pocket of the capsid.
- the canyon is the receptor-binding site.
- VP4 gene is the most conservative region in all the structure protein of HRVs.
- BCHO 19 was the unique microorganism detected in the nasopharyngeal aspirate sample from a patient (sample number BCHO 19) clinically diagnosed as bronchopneumonia suggests a close correlation between BCHO 19 and the symptoms of acute lower respiratory tract infection developed in this patient.
- the present invention provides primers, kits, and methods for specifically amplifying a strain of HRV-C in a sample by PCR amplification.
- the primers of the invention are designed targeting the region around the VP4 gene of BCHO 19.
- at least one primer of the invention comprises a nucleotide sequence corresponding to 18-25 consecutive nucleotides within the region from about 70 bp 5 '-upstream of VP4 gene to about 60 bp 3 '-downstream of VP4 gene of the genomic sequence of BCH019, i.e., from about nucleotide 556 to about nucleotide 886 of SEQ ID NO: 1.
- the region to be amplified by a primer pair of the invention includes a region about 70 bp 5 '-upstream of VP4 gene (the 3 '-terminal region of the 5'UTR, which is conservative for all the rhinovirus), the whole VP4 gene, and a region about 60 bp 3 '-downstream of VP4 gene (the 5 '-terminal region of the VP2 gene, which is conservative only for HRV-C).
- the forward primer is designed according to the sequence of the 3 '-terminal region of the 5'UTR, which is conservative for all the rhino virus
- the reverse primer is designed according to the sequence of the 5'- terminal region of the VP2 gene, which is conservative only for HRV-C.
- the designing of a primer for amplifying a given nucleotide sequence is within the reach of those skilled in the art.
- Softwares to assist the designing of a primer are available in the art, for example, Vector NTI Advance 10 (Invitrogen).
- Factors to be taken into account in the designing of primers include the length, Tm, avoiding of formation of secondary structure, etc, and are also known for those in the art.
- the forward primer is 556F (5'- ACTACTTTGGGTGTCCGTGTTTC-3', SEQ ID NO: 6), and the reverse primer is 886R (5 '-TTTCCRATAGTGATTTGCTTKAGCC-S ', SEQ ID NO: 7).
- the region covered by this primer pair is from 70 bp 5 '-upstream of VP4 gene to 59 bp 3 '-downstream of VP4 gene in genome of BCH019, i.e., from nucleotide 556 to nucleotide 886 of SEQ ID NO: 1.
- the primer pair of 556F and 886R was used to screen clinical samples and the results showed that some of the samples screened also contained rhino viruses which are belong to HRV Clade C.
- the present invention provides a pair of primers for amplifying a strain of HRV-C in a sample by PCR amplification, wherein the pair of primers comprises a forward primer 556F as set out in SEQ ID NO: 6 and a reverse primer 886R as set out in SEQ ID NO: 7.
- the present invention further provides a kit for amplifying a strain of HRV-C in a sample comprising at least one primer pair of the present invention as mentioned above.
- the present invention provides a method for detecting the presence of a strain of HRV-C in a sample from a mammal, comprising the steps of:
- the sample that can be tested according to the present invention can be nasal lavage, nasopharyngeal aspirate, bronchial lavage, or sputum.
- the method of the invention it is possible to further clarify and characterize whether the infectious agent of a common cold is HRV-C and thus it would benefit the patients with a common cold by treating the patients according to the specific infectious agent.
- This new Rhinovirus strain was identified from nasopharyngeal aspirate sample obtained from a 2 months old male infant (sample number BCHO 19) clinically diagnosed as bronchopneumonia.
- the patient was negative for anti-IgM against CMV, EBV, HSV and CoX.
- An exclusion test of the nasopharyngeal aspirate sample gave negative results for known respiratory tract viruses (including human parainfluenza viruses 1-4, influenza viruses, respiratory syncytial viruse, human enteroviruses, human rhinoviruses human coronaviruses 229E, NL63, HKUl and OC43, human metapneumovirus human adenoviruses and bocavirus).
- respiratory tract viruses including human parainfluenza viruses 1-4, influenza viruses, respiratory syncytial viruse, human enteroviruses, human rhinoviruses human coronaviruses 229E, NL63, HKUl and OC43, human metapneu
- Random PCR can be used to detect both DNA and RNA viral genomes [7] .
- 3 different viruses have been identified using random PCR: human bocavirus ⁇ , human KI polyomavirus ⁇ and human WU polyomavirus ⁇ ° ⁇
- the first amplification step of Random PCR uses a first random primer with a 5' end unique nucleotide universal sequence, containing restriction enzyme sites for subsequent cloning, followed by a degenerate hexa- or heptamer sequence at the 3' end.
- a subsequent PCR amplification step is carried out with a second, specific primer complementary to the 5' universal region of the first random primer.
- Nucleic acid was extracted by using the NucliSens basic kit extraction module (bioMerieux). 10 ⁇ l of nucleic acid was mixed with 0.4 ⁇ l of universal primer FR26RV-N (5 '-GCCGGAGCTCTGCAGATATCNNNNNN-S ', SEQ ID NO: 2) at 50 ⁇ M and 1.7 ⁇ l sterile deionized water. The samples were incubated at 65°C for 5 min., and then chilled on ice.
- the 50 ⁇ l reaction mixture consisted of 5 ⁇ l 10 ⁇ ExTaq buffer (Mg 2+ plus) (TaKaRa), each dNTP at 0.2 mM (TaKaRa), 40 pmol of the specific primer FR20RV (5'- GCCGGAGCTCTGCAGATATC-3', SEQ ID NO: 3) (which is specific for the universal primer FR26RV-N), and 2.5 units of ExTaq (TaKaRa). After 10 min at 94°C, 40 cycles of amplification (94°C for 1 min, 65°C for 1 min, and 72°C for 2 min.) were performed in GeneAmp® PCR System 9700 (Applied Biosystem).
- the amplification products obtained as above were purified by using a QIAquick PCR Purification Kit (Qiagen). Products were then separated on an agarose gel and fragments between ⁇ 500 and 2000 bp in length were excised and extracted by QIAquick Gel Extraction Kit (Qiagen). Purified PCR products were ligated to the pMD18-T vector (TaKaRa) and introduced into chemically competent E. coli DHlOB (Invitrogen). Bacteria were cultured on ampicillin-X-Gal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside) agar plates, allowing blue-white screening. White colonies were picked and cultured for 2 h in 1 ml of Luria-Bertani broth plus ampicillin.
- the 3 initial different clones represented 3 different fragments of a rhinovirus genome (Fig. 2B).
- the first was 307 bp covering the region of 5'UTR/VP4, the second was 494bp covering the region of VP2/VP3, and the third was 635 bp covering the region of 2C/3A.
- Series PCR primers were designed, with which most of genomic fragments were obtained step by step.
- the RACE system of Invitrogen was used to obtain the 5' end and 3' end terminal sequences of the genome.
- This new virus is identified as a rhinovirus and named BCHO 19, the entire genomic sequence of which is set out in Figure 1 and SEQ ID NO: 1.
- BCH019 spans 7121nt, including 5'UTR (626 nt), polyprotein coding sequence (6438 nt), 3'UTR (38 nt) and polyA tail (Fig. 2A).
- the organization of precursor polyprotein is same as all the HRV, which has a highly conserved translation initiation site (MGAQVS) and regions corresponding to the sequences encoding structural proteins VP4, VP2, VP3, VPl and non structural proteins 2A, 2B, 2C, 3A, 3B, 3C and 3D (Fig. 2A).
- BCHO 19 represents a distinct new human rhinovirus. Even comparing with HRV NAT045, the closest HRV strain in phylogenetic tree, the similarity between BCHO 19 and HRV NAT045 was only 66.7%. BCHO 19 and some other recently discovered rhinoviruses including HRV-QPM, HRV-NAT045, 001, HRV-C 024, 025, and 026 clearly belong to a separate clade, HRV-C.
- nucleic acid of sample BCHO 19 was extracted again.
- Newly designed specific primers targeting all the putative coding protein were used to amplify the genes.
- Primer VP3 (5'- GGGCTACCAACCAGACTACCAA-3', SEQ ID NO: 10) and primer VP3R (5'- CGATATGTTGTTACTAGGCTGTTC-3', SEQ ID NO: 11) were designed to amplify VP3 gene (Fig 4D).
- Primer 2A (5 '-GGACCCAGTGATTTATTTGTACA-S ', SEQ ID NO: 12) and primer 2BR (5 '-CTGCTTGGAGGGCGGTTTA-S ', SEQ ID NO: 13) were designed to amplify 2A and 2B genes (Fig 4D).
- Primer 2C (5 '-CAGTGGTGATGGTTGGCTC-S ', SEQ ID NO: 14) and primer 2CR (5 '-GCGTTGGAATATTGCATCTAG-S ', SEQ ID NO: 15) were designed to amplify 2C gene (Fig 4A).
- Primer 3A (5'- GATTAGGAGATTCTGAGACACCA-3', SEQ ID NO: 16) and primer 3CR (5'- CGCTGGGTGTCATTAAAGTATT-3', SEQ ID NO: 17) were designed to amplify 3 A, 3B and 3C genes (Fig 4D).
- Primer 3D (5 '-TGCTATCACACATGTCCAAGA-S ', SEQ ID NO: 18) and primer 3DR (5 '-GAAATTGTCAAGCCACTGC-S ', SEQ ID NO: 19) were designed to amplify 3D gene (Fig 4C).
- Figure 4 shows the PCR products obtained by using primers targeting the protein coding regions of BCHO 19. At least 3 clones of each PCR products were sequenced to make sure the accuracy of the sequence of each region. The result confirmed the existence of the rhinovirus BCHO 19 in this sample and the accuracy of the sequence.
- Example 3 Detection of HRV-Cs in samples from patients with respiratory infections Designing PCR primers for determining human rhinovirus of group C VP4 gene is the most conservative region in all the structure protein, so the full-length sequences of this region of all known HRVs were compared in order to design specific primers for HRV-C.
- a forward primer 556F (5 '-ACTACTTTGGGTGTCCGTGTTTC-S ', SEQ ID NO: 6) and a reverse primer 886R (5 '-TTTCCRATAGTGATTTGCTTKAGCC-S ', SEQ ID NO: 7) were designed which are directed to the region from 70 bp 5 '-upstream of VP4 gene to 59 bp 3 '-downstream of VP4 gene of SEQ ID NO: 1.
- the forward primer 556F was designed according to the sequence of the 3 '-terminal region of the 5'UTR, which is conservative for all the rhinovirus, while the reverse primer 886R was designed according to the sequence of the 5 '-terminal region of the VP2 gene, which is conservative only for HRV-C.
- primers 556F and 886R were used to screen clinical samples for the evidence of infection with strains of HRV-C.
- Nucleic acid was extracted by using the NucliSens basic kit extraction module (bioMerieux). Nucleic acid (1 ⁇ l) was used as template for the PCR.
- the 20 ⁇ l reaction reagent mixture consisted of 10 ⁇ l 2xReaction Mix (Invitrogen), 1 ⁇ l SuperscriptTMIIIRT/platinum® Taq Mix (Invitrogen), 20 pmol each of the primers 556F (5'- ACTACTTTGGGTGTCCGTGTTTC-3', SEQ ID NO: 6) and 886R (5'- TTTCCRATAGTGATTTGCTTKAGCC-3', SEQ ID NO: 7). After 45 min.
- Table 1 Clinical manifestations of 14 HRV-C positive cases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The characterization of a new strain of human rhinovirus of genetic group C (HRV-C) as well as methods and kits for detecting the presence of HRV-C by PCR amplification are provided.
Description
A newly Identified Human Rhinovirus of HRV-C and Methods and Kits for Detecting
HRV-Cs
Field of the Invention
The present invention generally relates to the identification and detection of human rhino viruses. More particularly, the present invention relates to the characterization of a new strain of human rhinovirus of genetic group C (HRV-C) as well as methods and kits for detecting the presence of HRV-C, for instance, by PCR amplification.
Background of the Invention
Human rhinoviruses (HRVs) are the major cause of common cold. Although the majority of HRV infections only cause mild disease, Rhinoviruses can also cause lower respiratory tract infections resulting in severe disease in children, in the elderly and in immunosuppressed patients. Their impact on overall morbidity and their economic cost worldwide are considerable.
Rhinoviruses are small RNA, non-enveloped, viruses belonging to the family picornaviridae . Until now, over 100 serotypes of Rhinoviruses have been identified by specific antisera in a collaborative program supported by the World Health Organization (WHO). Rhinoviruses are divided into major (90%) and minor (10%) groups, according to their cellular receptor usage. An alternative classification, dividing the viruses into group A and B, based on sensitivity to antiviral compounds and correlating with sequence similarities and pathogenicity, has also been proposed ^.
In recent years, some researchers have identified new rhinoviruses which cannot be classified into traditional group A or B. McErlean et al ^ screened 1244 nasopharyngeal aspirates collected from patients aged from 1 day to 80 years who presented to Queensland hospitals or general practitioners with symptoms of acute respiratory tract infections during 2003. Among the samples screened, 17 were identified as new rhinovirus positive and the authors named the new rhinovirus as HRV-QPM, which was classified into HRV- A2. The whole genome of HRV-QPM is shorter than all other known HRVs' and isolation of the strain was unsuccessful using human cell lines HeLa-Ohio, A549, MRC-5 and WB 8. Kistler et al ^ used virochip to test samples from recruited adults who had cold symptoms
from the fall of 2001 to December of 2004. They found 5 divergent HRVs named as HRVX', which possessed slightly more sequence similarity to HRV-A than to HRV-B reference serotypes. None of the divergent HRVX' isolates were culturable. Lee et al ^ used Respiratory Multicode Assay to analyze nasal lavage samples of infants. They found 5 distinct strains and proposed that they represent a new HRV genetic group (HRV-C). None of the samples containing the new HRV strains produced cytopathic effect (CPE) in standard WI-38 or MRC-5 cell cultures used for the detection and isolation of HRV. Using RT-PCR method, Lau et al ^ screened 200 Nasopharyngeal Aspirates (NPAs) collected from hospitalized children during a 1-year period (November 2004 to October 2005). They found 21 positive for HRV which belonged to a distinct genetic cluster, i.e., clade C, with nucleotide identity of <63% to known HRV-A strains and nucleotide identity of <61% to known HRV-B strains. Renwick et al ^ used MassTag PCR to investigate 97 nasopharyngeal aspirates from children hospitals during the interval of 2003-2006. They found 30 HRV sequences which did not match with known HRVA, HRVB, or Human Enterovirus (HEV) sequences.
Summary of the Invention
The present invention is based on the discovery of a new Rhinovirus strain of HRV-C, named BCHO 19, which is believed to be associated with severe respiratory illness. The genomic sequence of BCHO 19 is set out in Figure 1 and SEQ ID NO: 1. The organization of the genome of BCHO 19 is depicted in Figure 2.
Accordingly, in one aspect, the present invention relates to an isolated HRV-C Rhinovirus having a RNA genome, said genome comprising a polynucleotide sequence selected from the group consisting of:
(i) a sequence identified as SEQ ID NO: 1,
(ii) a sequence which exhibits at least 75% identity, preferably at least 80%,
85%, 90% or 95% identity with SEQ ID NO: 1, and (iii) a complementary sequence of a sequence identified in (i) or (ii). Furthermore its genome comprises at least one reading frame encoding a polyprotein, the sequence of which is identified as SEQ NO: 20.
The invention also relates to nucleic acid sequences of said virus as well as the use of the above polynucleotide or fragments thereof in designing primers or probes for detecting HRV-C Rhinovirus in a sample.
The present invention also concerns nucleic fragments comprising or consisting of at least 50 consecutive nucleotides, preferably at least 100, 150 or 200 consecutive nucleotides, belonging to a nucleotide sequence starting at nucleotide 627 and ending at nucleotide 7064 of SEQ ID NO: 1, or belonging to a nucleotide sequence which exhibits at least 85% identity, preferably at least 90 or 95% identity with the nucleotide sequence starting at nucleotide 627 and ending at nucleotide 7064 of SEQ ID NO: 1 or their complementary sequences; and especially the following fragments respectively identified in SEQ ID NO: 21 (VP4 nt 627-827 inclusive), SEQ ID NO: 22 (VP2 nt 828-1613 inclusive) and SEQ ID NO: 23 (PCR product nt 556-886 inclusive) and the variants which exhibit at least 85% identity, preferably at least 90 or 95% identity, respectively or their complementary sequences.
In another aspect, the present invention provides a pair of primers for amplifying a strain of HRV-C in a sample by PCR amplification, wherein at least one primer comprises a nucleotide sequence which consists of 18 to 30 consecutive nucleotides, especially 18 to 25 consecutive nucleotides, within the region from about nucleotide 556 to about nucleotide 886 of SEQ ID NO: 1. In a preferred embodiment, the pair of primers comprises a forward primer 556F as set out in SEQ ID NO: 6 and a reverse primer 886R as set out in SEQ ID NO: 7.
In another aspect, the present invention provides a kit for PCR amplifying a strain of HRV-C in a sample comprising at least one primer pair of the present invention as mentioned above.
In a further aspect, the present invention provides a method for detecting the presence of a strain of HRV-C in a sample, comprising the steps of:
(a) extracting nucleic acid from the sample,
(b) amplifying the extracted nucleic acid, and
(c) determining the presence of one or more nucleic acid sequences, wherein the amplification step is, for instance, performed by RT-PCR, by using at least one primer pair of the present invention as mentioned above.
Other techniques exist for amplifying a target in a sample. By way of example NASBA and TMA technologies are cited.
The sample is selected from the group consisting of human oral and nasal samples (obtained from nasal lavage, nasopharyngeal aspirate, bronchial lavage, sputum, oral and nasal swabs) and viral culture supernatants.
The nucleotide sequences listed as SEQ ID Nos: 1, 21, 22 and 23 correspond to cDNA obtained from the reverse transcription of genomic RNA.
In other aspects, the invention concerns:
(a) an isolated protein:
- encoded by a polynucleotide sequence selected from the group consisting of: (i) a sequence identified as SEQ ID NO: 1, (ii) a sequence which exhibits at least 75% identity with SEQ ID NO: 1, and (iii) a complementary sequence of a sequence identified in (i) or (ii); or
- encoded by a nucleic fragment of a polynucleotide, the nucleotide sequence of which is defined above in (i), (ii) or (iii); or
- comprising or consisting of an amino acid sequence identified as SEQ. ID. NO: 20;
(b) a polypeptide the amino acid sequence of which comprises or consists of at least 15 consecutive amino acids, preferably of at least 20 consecutive amino acids, advantageously of at least 30 consecutive amino acids of a protein as defined above in (a);
(c) an antibody having specificity against an epitope of a protein as defined above in (a) or (b);
(d) a method for detecting the presence of a strain of HRV-C in a sample comprising the steps of contacting the sample with a protein as defined above in (a) or with a polypeptide as defined above in (b) and detecting the presence of an immune complex formed between the protein or polypeptide and anti-HRV-C antibodies, for example by immuno-enzymatic methods including colorimetric, fluorescent, luminescent or electrochemistry detection such as Western Blot, sandwich immunoassay and competition technology; the sample being preferably a human sample selected from the group consisting of blood, plasma and serum;
(e) a method for detecting the presence of a strain of HRV-C in a sample comprising the steps of contacting the sample with at least one anti-HRV-C antibody having a
specificity against an epitope of a HRV-C protein of the strain and detecting the presence of an immune complex of antibody/HRV-C protein, for example by immuno-enzymatic methods including colorimetric, fluorescent, luminescent or electrochemistry detection such as Western Blot, sandwich immunoassay and competition technology; the sample being preferably selected from the group consisting of human oral and nasal samples (obtained from nasal lavage, nasopharyngeal aspirate, bronchial lavage, sputum, oral and nasal swabs) and viral culture supernatants;
(f) a kit for the diagnosis of a strain of HRV-C characterized in that it comprises at least one protein or at least one polypeptide as defined above in (a) or (b);
(g) a kit for the diagnosis of a strain of HRV-C characterized in that it comprises at least one antibody as defined above in (c).
Proteins and polypeptides can be produced by recombinant technology or chemical synthesis.
Antibodies can be polyclonal antibodies, monoclonal antibodies, recombinant antibodies or fragments thereof, such as Fab, Fab', Fab'2, scFv, Fv.
These and other aspects, advantages, and features of the invention will become apparent from the following figures and detailed description of the specific embodiments.
Brief Description of the Drawings
Figure 1 set out the genomic sequence of BCHO 19.
Figure 2 depicts the genomic organization of BCHO 19 (panel A) and positions of the 3 different clones initially obtained by random PCR (panel B).
Figure 3 shows the results of phylogenetic analysis of HRVs: bootstrapped neighbor- joining tree was constructed based on full-length nucleotide sequence of all known HRVs and some HEVs.
Figure 4 shows the PCR products obtained by using primers targeting protein coding regions of BCHO 19. The PCR products were separated on agarose gel.
Detailed Description of the Invention
The present invention is based on the discovery of a new Rhinovirus strain, named BCHO 19, which is believed to be associated with severe respiratory illness.
The full genomic sequence of BCHO 19 is set out in Figure 1 and SEQ ID NO: 1. Genomic characterization showed that the full genome of BCHO 19 spans 7121nt, including a 5'-UTR (626nt), a polyprotein coding sequence (6438nt), a 3'-UTR (38nt), and a polyA tail (Fig. 2). The organization of the coding region of the precursor polyprotein in BCHO 19 is same as that in all the known HRVs, which has a highly conserved translation initiation site (encoding MGAQVS) and regions corresponding to the capsid genes VP4, VP2, VP3, VPl and non-structural genes 2A, 2B, 2C, 3A, 3B, 3C and 3D.
After phylogenetic analysis with software MEGA 4, a bootstrapped neighbor-joining tree based on full-length nucleotide sequence of all known HRVs and some HEVs was constructed and it showed that BCHO 19 is a distinct rhinovirus which belongs to group C of HRV rather than to group A or B (Fig. 3). VPl is the major protein to form the canyon and the drug-binding pocket of the capsid. The canyon is the receptor-binding site. VP4 gene is the most conservative region in all the structure protein of HRVs.
The fact that BCHO 19 was the unique microorganism detected in the nasopharyngeal aspirate sample from a patient (sample number BCHO 19) clinically diagnosed as bronchopneumonia suggests a close correlation between BCHO 19 and the symptoms of acute lower respiratory tract infection developed in this patient.
In another aspect, the present invention provides primers, kits, and methods for specifically amplifying a strain of HRV-C in a sample by PCR amplification. The primers of the invention are designed targeting the region around the VP4 gene of BCHO 19. In one embodiment of the invention, at least one primer of the invention comprises a nucleotide sequence corresponding to 18-25 consecutive nucleotides within the region from about 70 bp 5 '-upstream of VP4 gene to about 60 bp 3 '-downstream of VP4 gene of the genomic sequence of BCH019, i.e., from about nucleotide 556 to about nucleotide 886 of SEQ ID NO: 1. In another embodiment, the region to be amplified by a primer pair of the invention includes a region about 70 bp 5 '-upstream of VP4 gene (the 3 '-terminal region of the 5'UTR, which is conservative for all the rhinovirus), the whole VP4 gene, and a region about 60 bp 3 '-downstream of VP4 gene (the 5 '-terminal region of the VP2 gene, which is conservative only for HRV-C). In this embodiment, the forward primer is designed according to the sequence of the 3 '-terminal region of the 5'UTR, which is conservative for
all the rhino virus, while the reverse primer is designed according to the sequence of the 5'- terminal region of the VP2 gene, which is conservative only for HRV-C.
The designing of a primer for amplifying a given nucleotide sequence is within the reach of those skilled in the art. Softwares to assist the designing of a primer are available in the art, for example, Vector NTI Advance 10 (Invitrogen). Factors to be taken into account in the designing of primers include the length, Tm, avoiding of formation of secondary structure, etc, and are also known for those in the art.
In a specific embodiment of the present invention, the forward primer is 556F (5'- ACTACTTTGGGTGTCCGTGTTTC-3', SEQ ID NO: 6), and the reverse primer is 886R (5 '-TTTCCRATAGTGATTTGCTTKAGCC-S ', SEQ ID NO: 7). The region covered by this primer pair is from 70 bp 5 '-upstream of VP4 gene to 59 bp 3 '-downstream of VP4 gene in genome of BCH019, i.e., from nucleotide 556 to nucleotide 886 of SEQ ID NO: 1.
As shown in the examples, the primer pair of 556F and 886R was used to screen clinical samples and the results showed that some of the samples screened also contained rhino viruses which are belong to HRV Clade C.
Accordingly, in a preferred embodiment, the present invention provides a pair of primers for amplifying a strain of HRV-C in a sample by PCR amplification, wherein the pair of primers comprises a forward primer 556F as set out in SEQ ID NO: 6 and a reverse primer 886R as set out in SEQ ID NO: 7.
The present invention further provides a kit for amplifying a strain of HRV-C in a sample comprising at least one primer pair of the present invention as mentioned above.
In a further embodiment, the present invention provides a method for detecting the presence of a strain of HRV-C in a sample from a mammal, comprising the steps of:
(a) extracting nucleic acid from the sample,
(b) amplifying the extracted nucleic acid, and
(c) determining the presence of nucleic acid sequences(s) specific for HRV-C, wherein the amplification step is, for instance, performed by an RT-PCR amplification by using at least one primer pair of the present invention.
The sample that can be tested according to the present invention can be nasal lavage, nasopharyngeal aspirate, bronchial lavage, or sputum.
With the method of the invention, it is possible to further clarify and characterize whether the infectious agent of a common cold is HRV-C and thus it would benefit the patients with a common cold by treating the patients according to the specific infectious agent.
Examples
Example 1. Identification of a new human rhinovirus of group C, named BCH019
Case introduction
This new Rhinovirus strain was identified from nasopharyngeal aspirate sample obtained from a 2 months old male infant (sample number BCHO 19) clinically diagnosed as bronchopneumonia. The patient was negative for anti-IgM against CMV, EBV, HSV and CoX. An exclusion test of the nasopharyngeal aspirate sample gave negative results for known respiratory tract viruses (including human parainfluenza viruses 1-4, influenza viruses, respiratory syncytial viruse, human enteroviruses, human rhinoviruses human coronaviruses 229E, NL63, HKUl and OC43, human metapneumovirus human adenoviruses and bocavirus). There were only normal bacteria floras in sputum culture. The nucleic acid was extracted from the nasopharyngeal aspirate sample of this patient and amplified by Random PCR in order to find unknown pathogenic microorganisms.
Random PCR
Random PCR can be used to detect both DNA and RNA viral genomes [7]. 3 different viruses have been identified using random PCR: human bocavirus ^, human KI polyomavirus ^ and human WU polyomavirus ^°\ The first amplification step of Random PCR uses a first random primer with a 5' end unique nucleotide universal sequence, containing restriction enzyme sites for subsequent cloning, followed by a degenerate hexa- or heptamer sequence at the 3' end. After the first amplification step, a subsequent PCR amplification step is carried out with a second, specific primer complementary to the 5' universal region of the first random primer.
Nasopharyngeal aspirates were obtained from hospitalized children in Beijing Children Hospital in April 2007. To test the respiratory tract samples that were found negative for common pathogenic microorganisms, a random PCR method previously
described ^8' 1^ was used with some modifications. In brief, the samples were centrifuged at 3000 rpm for 10 min. in a Sigma 3k30 table-top centrifuge to remove cell debris. 200 μl of the cell-free supernatant was filtered through a 0.2 μm Super® Membrane (Acrodisc® 25mm Syringe Filter, Pall). 20 μl of RNase free DNase I (Promega) was added, and the samples were incubated for 60 min. at 37°C. Nucleic acid was extracted by using the NucliSens basic kit extraction module (bioMerieux). 10 μl of nucleic acid was mixed with 0.4 μl of universal primer FR26RV-N (5 '-GCCGGAGCTCTGCAGATATCNNNNNN-S ', SEQ ID NO: 2) at 50 μM and 1.7 μl sterile deionized water. The samples were incubated at 65°C for 5 min., and then chilled on ice. A reaction reagent mixture of 7.9 μl containing 4 μl of 5xFirst-Strand buffer (Invitrogen), 2 μl of 100 mM DTT (Invitrogen), 1 μl solution containing each dNTP (Invitrogen) at 10 mM, 8 units (0.4 μl) of recombinant RNase inhibitor (Ambion), and 100 units (0.5 μl) of Superscript II reverse transcriptase (Invitrogen) was added. The reaction mixture was incubated at 25°C for 10 min. and then 42°C for 50 min. After a denaturation step at 94°C for 3 min. and chilling on ice, 2.5 units (0.5 μl) of 3'- 5' exo-Klenow DNA polymerase (New England Biolabs) were added, and the reaction mixture was incubated at 37°C for 1 h, followed by an enzyme inactivation step at 75°C for 10 min. 5 μl of each reaction mixture was used as a template in a subsequent PCR. The 50 μl reaction mixture consisted of 5 μl 10χExTaq buffer (Mg2+ plus) (TaKaRa), each dNTP at 0.2 mM (TaKaRa), 40 pmol of the specific primer FR20RV (5'- GCCGGAGCTCTGCAGATATC-3', SEQ ID NO: 3) (which is specific for the universal primer FR26RV-N), and 2.5 units of ExTaq (TaKaRa). After 10 min at 94°C, 40 cycles of amplification (94°C for 1 min, 65°C for 1 min, and 72°C for 2 min.) were performed in GeneAmp® PCR System 9700 (Applied Biosystem).
Cloning and sequencing PCR products
The amplification products obtained as above were purified by using a QIAquick PCR Purification Kit (Qiagen). Products were then separated on an agarose gel and fragments between ^ 500 and 2000 bp in length were excised and extracted by QIAquick Gel Extraction Kit (Qiagen). Purified PCR products were ligated to the pMD18-T vector (TaKaRa) and introduced into chemically competent E. coli DHlOB (Invitrogen). Bacteria were cultured on ampicillin-X-Gal (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside)
agar plates, allowing blue-white screening. White colonies were picked and cultured for 2 h in 1 ml of Luria-Bertani broth plus ampicillin.
For subsequent PCR amplification of the cloned inserts, 1 μl of bacterial suspension was added to the PCR mixture containing 0.2 μM of the pMD18-T vector primers M13fwd (5 '-CGCCAGGGTTTTCCCAGTCACGAC-S ', SEQ ID NO: 4) and M13rev (5'- GAGCGGATAACAATTTCACACAGG-3', SEQ ID NO: 5), 2 mM of each dNTP, 2 μl 10χExTaq buffer, and 1.25 U of Taq DNA polymerase in a total reaction volume of 20 μl. Cycling was performed as follows: 1 cycle of 94°C for 3 min., followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 1 min.
To avoid repeated sequencing of the same cloned PCR products or primer dimers, only PCR products that were larger than 250 bp and that differed in size were sent to a commercial company to get the sequence.
Obtaining the full genomic sequence of BCHO 19
From the sample of a patient with the index sample number BCHO 19 who was negative for all the familiar respiratory tract viruses and bacteria tested, 185 clones of random PCR were obtained, and 6 of them were found as rhino virus positive, representing 3 different fragments of a rhinovirus genome. Sequences of 3 initial different clones were then used to design new PCR primers to ligate the gaps step by step. 1 μl of nucleic acid extracted from BCHO 19 was used as template for the one-step RT PCR. The 20 μl reaction mixture consisted of 10 μl 2xReaction Mix (Invitrogen), 1 μl Superscript™IIIRT/platinum® Taq Mix (Invitrogen), 20 pmol each of the primers. After 45min at 48°C and 3 min. at 94°C, 35 cycles of amplification were performed. Products were visualized on an agarose gel and extracted, then ligated with pMD18-T vector. After transformed into competent DHlOB and cultured, the clones containing the product were sent to a commercial company to get the sequence. The terminal sequences were amplified using RACE system for rapid amplification of cDNA ends (Invitrogen).
Sequences obtained were analyzed for sequence homology with nucleotide sequences available in the GenBank database by using the BLASTn and the MEGA 4 software.
Characterization of the genome ofBCH019
The 3 initial different clones represented 3 different fragments of a rhinovirus genome (Fig. 2B). The first was 307 bp covering the region of 5'UTR/VP4, the second was 494bp covering the region of VP2/VP3, and the third was 635 bp covering the region of 2C/3A. Series PCR primers were designed, with which most of genomic fragments were obtained step by step. Then the RACE system of Invitrogen was used to obtain the 5' end and 3' end terminal sequences of the genome. This new virus is identified as a rhinovirus and named BCHO 19, the entire genomic sequence of which is set out in Figure 1 and SEQ ID NO: 1.
The genome of BCH019 spans 7121nt, including 5'UTR (626 nt), polyprotein coding sequence (6438 nt), 3'UTR (38 nt) and polyA tail (Fig. 2A). The organization of precursor polyprotein is same as all the HRV, which has a highly conserved translation initiation site (MGAQVS) and regions corresponding to the sequences encoding structural proteins VP4, VP2, VP3, VPl and non structural proteins 2A, 2B, 2C, 3A, 3B, 3C and 3D (Fig. 2A).
Phylogenetic analysis
Phylogenetic tree was constructed based on alignments of BCHO 19 with all the complete sequence of HRV serotypes (Human rhinovirus sp. isolate NAT045 [F077280], Human rhinovirus sp. isolate NATOOl [EF077279], Human rhinovirus QPM [EF 186077], Human rhinovirus C strain 026 [EF582387], Human rhinovirus C strain 025 [EF582386], Human rhinovirus C strain 024 [EF582385], HRV89 [NC 001617], B [NC 001490], 93 [EF173425], 52 [EF173424], 37 [EF173423], 3 [EF173422], 27 [EF173421], 17 [EF173420], 94 [EF173419], 78 [EF173418], 64 [EF173417], 24 [EF173416], 12 [EF173415], 11 [EF173414], 30 [DQ473512], 55 [DQ473511], 75 [DQ473510], A [DQ473509], 28 [DQ473508], 53 [DQ473507], 46 [DQ473506], 36 [DQ473505], 88 [DQ473504], 7 [DQ473503], 76 [DQ473502], 34 [DQ473501], 59 [DQ473500], 44 [DQ473499], 10 [DQ473498], 23 [DQ473497], 49 [DQ473496], 38 [DQ473495], 74 [DQ473494], 15 [DQ473493], 73 [DQ473492], 41 [DQ473491], 4 [DQ473490], 70 [DQ473489], 48 [DQ473488 ], 35 [DQ473487], 6 [ DQ473486], 2 [X02316 ], 39 [AY751783], 14 [K02121], IB [D00239], 16 [L24917]) as well as 10 HEV (Human enterovirus 68 [EF107098], Human enterovirus 70 [DQ201177], Human poliovirus type 1 [VOl 148], Poliovirus type 2 [X00595], Human coxsackievirus A2 [AY421760], Human
coxsackievirus A6 [AY421764], Echovirus 1 [AF029859], Human echovirus 6 [AY302558], Coxsackievirus B2 [AF081485], and Human coxsackievirus Al [AF499635]) sequences (Fig. 3).
It was found that the sequence of BCHO 19 represents a distinct new human rhinovirus. Even comparing with HRV NAT045, the closest HRV strain in phylogenetic tree, the similarity between BCHO 19 and HRV NAT045 was only 66.7%. BCHO 19 and some other recently discovered rhinoviruses including HRV-QPM, HRV-NAT045, 001, HRV-C 024, 025, and 026 clearly belong to a separate clade, HRV-C.
Example 2. Verification of the genomic sequence of BCH019
To verify the sequence of BCHO 19, nucleic acid of sample BCHO 19 was extracted again. Newly designed specific primers targeting all the putative coding protein were used to amplify the genes. Primer VP4 (5 '-ATGGGTGCACAAGTGAGTAA-S ', SEQ ID NO: 8) and primer VP2R (5 '-GCTATTGCTTTTGGGTTTG-S ', SEQ ID NO: 9) were designed to amplify VP4 and VP2 genes (Fig 4B). Primer VP3 (5'- GGGCTACCAACCAGACTACCAA-3', SEQ ID NO: 10) and primer VP3R (5'- CGATATGTTGTTACTAGGCTGTTC-3', SEQ ID NO: 11) were designed to amplify VP3 gene (Fig 4D). Primer 2A (5 '-GGACCCAGTGATTTATTTGTACA-S ', SEQ ID NO: 12) and primer 2BR (5 '-CTGCTTGGAGGGCGGTTTA-S ', SEQ ID NO: 13) were designed to amplify 2A and 2B genes (Fig 4D). Primer 2C (5 '-CAGTGGTGATGGTTGGCTC-S ', SEQ ID NO: 14) and primer 2CR (5 '-GCGTTGGAATATTGCATCTAG-S ', SEQ ID NO: 15) were designed to amplify 2C gene (Fig 4A). Primer 3A (5'- GATTAGGAGATTCTGAGACACCA-3', SEQ ID NO: 16) and primer 3CR (5'- CGCTGGGTGTCATTAAAGTATT-3', SEQ ID NO: 17) were designed to amplify 3 A, 3B and 3C genes (Fig 4D). Primer 3D (5 '-TGCTATCACACATGTCCAAGA-S ', SEQ ID NO: 18) and primer 3DR (5 '-GAAATTGTCAAGCCACTGC-S ', SEQ ID NO: 19) were designed to amplify 3D gene (Fig 4C).
Figure 4 shows the PCR products obtained by using primers targeting the protein coding regions of BCHO 19. At least 3 clones of each PCR products were sequenced to make sure the accuracy of the sequence of each region. The result confirmed the existence of the rhinovirus BCHO 19 in this sample and the accuracy of the sequence.
Example 3. Detection of HRV-Cs in samples from patients with respiratory infections Designing PCR primers for determining human rhinovirus of group C VP4 gene is the most conservative region in all the structure protein, so the full-length sequences of this region of all known HRVs were compared in order to design specific primers for HRV-C. A forward primer 556F (5 '-ACTACTTTGGGTGTCCGTGTTTC-S ', SEQ ID NO: 6) and a reverse primer 886R (5 '-TTTCCRATAGTGATTTGCTTKAGCC-S ', SEQ ID NO: 7) were designed which are directed to the region from 70 bp 5 '-upstream of VP4 gene to 59 bp 3 '-downstream of VP4 gene of SEQ ID NO: 1. The forward primer 556F was designed according to the sequence of the 3 '-terminal region of the 5'UTR, which is conservative for all the rhinovirus, while the reverse primer 886R was designed according to the sequence of the 5 '-terminal region of the VP2 gene, which is conservative only for HRV-C.
To evaluate the incidence of HRV-C infection, primers 556F and 886R were used to screen clinical samples for the evidence of infection with strains of HRV-C.
Samples were extracted and amplified individually. Positive and negative controls were included in each experiment. Nucleic acid was extracted by using the NucliSens basic kit extraction module (bioMerieux). Nucleic acid (1 μl) was used as template for the PCR. The 20 μl reaction reagent mixture consisted of 10 μl 2xReaction Mix (Invitrogen), 1 μl Superscript™IIIRT/platinum® Taq Mix (Invitrogen), 20 pmol each of the primers 556F (5'- ACTACTTTGGGTGTCCGTGTTTC-3', SEQ ID NO: 6) and 886R (5'- TTTCCRATAGTGATTTGCTTKAGCC-3', SEQ ID NO: 7). After 45 min. at 48°C and 3 min at 94°C, 35 cycles of amplification (94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min.) were performed. Products were visualized on an agarose gel. The expected product size was 330 bp. All PCR products were sequenced to confirm that they were specific for HRV-C.
Detection of HRV-C infection
298 samples from BCH were screened by primers 556F and 886R and additional 13 samples were found HRV-C positive (Table 1). There were 12 males and 1 female. The age range was from 1 month 6 days to 3 years. The cases were gathered from emergency ward,
pediatric ward, pediatric intensive care unit (PICU) respectively. Rhinovirus is the unique respiratory virus tested in 8 cases. None cases occurred in summer (July, August and September) 2007.
Because human rhinovirus of group C is a new clade, so far it is not known if the rhinovirus of group C also has as many types as group A or B and its distribution in patients of acute respiratory tract infection. The inventors found 13 additional samples which were HRV-C positive. The result indicates that infection of the rhinovirus of group C might be common and the clinical manifestations are different as compared with infections of rhinovirus of group A or B. These data also suggest that like HRV-A and HRV-B groups, HRV-C strains are also highly genetically diverse.
Table 1 : Clinical manifestations of 14 HRV-C positive cases.
Date of
Sample hospitalizati Gender Age Clinical manifestations Diagnosis Ward Codetection
No. on
BCHO 19 April 04 M 1 mon 30days Snivel, cough Bronchopneumonia Pediatric ward -
BCH057 May 09 M 15 mon Fever (39°C), cough and asthma Bronchopneumonia Pediatric ward -
Snivel, cough, asthma, vomit, diarrhea,
BCH083 June 19 M 31 mon Bronchial asthma Pediatric ward - rhonchi
Cough, sputum, asthma, rhonchi and moist Critical care
BCH200 October 15 M 8 mon Peribronchiolitis rale room
BCH217 October 22 F 5 mon Cough, sputum, vomit, fever (400C), rhonchi Pneumonia Pediatric ward -
BCH220 October 21 M 17 mon Snivel, cough, fever (38.6°C), moist rale Pneumonia pediatric ward PIV 3
BCH221 October 23 M 7 mon Cough, sputum, fever (37.8°C), moist rale Bronchopneumonia Pediatric ward RSV A
BCH237 October 30 M 1 mon 14days Cough, moist rale Bronchopneumonia PICU -
BCH242 October 31 M 3 yr Cough, fever (38°C) Pneumonia Pediatric ward -
BCH249 NovemberOβ M 1 mon 6days Cough, moist rale Bronchopneumonia PICU -
BCH250 November05 M 3 mon Cough, sputum, moist rale Bronchiolitis Pediatric ward RSV A
Ppediatric
BCH264 October 25 M 3 mon Fever (38°C) Infant hepatitis syndrome RSV A ward
November RSV A,
BCH277 M 8 mon 14 days Snivel, cough, fever (39°C) Pneumonia Pediatric ward 10 NL63
November Emergency
BCH297 M 50 days Cough, sputum, rhonchi and moist rale Pneumonia RSV A 20 room
References:
1. Papadopoulos NG and Johnston SL. Rhino viruses. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD and Schoub BD, Edited. Principles and Practice of Clinical Virology, Fifth Edition. 2004 John Wiley & Sons Ltd. Pp 361 - 362. 2. McErlean P, Shackelton LA, Lambert SB, Nissen MD, Sloots TP, and Mackay IM. 2007. Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in infants with bronchiolitis. J. Clin.Virol. 39:67 - 75.
3. Kistler A, Avila PC, Rouskin S, Wang D, Ward T, Yagi S, Schnurr D, Ganem D, DeRisi JL. and Boushey HA. 2007. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human corona virus and human rhinovirus diversity. J Infect Dis 196:817 - 25.
4. Lee WM, Kiesner C, Pappas T, Lee I, Grindle K, Jartti T, Jakiela B. 2007. A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants. PIoS ONE 2(10):e966. 5. Lau SKP, Yip CCY, Tsoi Hoi-wah, Lee RA, So Lok-yee, Lau Yu-lung, Chan Kwok-hung, Woo PCY, and Yuen Kwok-yung. 2007. Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J Clin Microbiol. 45(l l):3655 - 64.
6. Renwick N, Schweiger B, Kapoor V, Liu Zhiqiang, Villari J, Bullmann R, Miething R, Briese T, and Lipkin W. I. 2007. A recently identified rhinovirus genotype is associated with severe respiratory-tract infection in children in Germany. J Infect Dis. 196:1754 - 60. 7. Ambrose HE and Clewley JP. Virus discovery by sequence-independent genome amplification. 2006. Rev. Med. Virol. 16: 365 - 83.
8. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, et al. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 102: 12891 - 6. 9. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, et al. 2007.
Identification of a third human polyomavirus. J Virol 81 : 4130 - 6. 10. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, et al. 2007. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 3(5): e64.
l l. Stang A, Korn K, Wildner O, andϋberlalK. 2005. Characterization of virus isolates by particle-associated nucleic acid PCR. J Clin Microbiol. 43(2):716 - 20.
Claims
1. An isolated HRV-C Rhinovirus having a RNA genome, said genome comprising a polynucleotide sequence selected from the group consisting of: (iv) a sequence identified as SEQ ID NO: 1,
(v) a sequence which exhibits at least 75% identity with SEQ ID NO: 1, and (vi) a complementary sequence of a sequence identified in (i) or (ii).
2. Virus according to claim 1, characterized in that its genome comprises at least one reading frame encoding a polyprotein, the sequence of which is identified as SEQ NO: 20.
3. Nucleic acid sequence capable of being obtained from the genome of the virus as defined in claim 1.
4. Nucleic fragment, characterized in that it comprises or consists of at least 50 consecutive nucleotides, preferably at least 100 consecutive nucleotides, belonging to a nucleotide sequence starting at nucleotide 627 and ending at nucleotide 7064 of SEQ ID NO: 1 or belonging to a nucleotide sequence which exhibits at least 85% identity with the nucleotide sequence starting at nucleotide 627 and ending at nucleotide 7064 of SEQ ID NO: 1 or their complementary sequences.
5. Nucleic fragment according to claim 4, characterized in that it is selected from the group consisting of:
- SEQ ID NO: 21, a sequence which exhibits at least 85% identity with SEQ ID NO: 21 or their complementary sequences,
- SEQ ID NO: 22, a sequence which exhibits at least 85% identity with SEQ ID NO: 22 or their complementary sequences, and - SEQ ID NO: 23, a sequence which exhibits at least 85% identity with SEQ ID
NO: 23 or their complementary sequences.
6. A pair of primers for amplifying a HRV-C strain in a sample by PCR amplification, wherein at least one primer has a sequence which consists of 18-30 consecutive nucleotides within the region from about nucleotide 556 to about nucleotide 886 of SEQ ID NO: 1.
7. The pair of primers according to claim 6, wherein the forward primer consists of a nucleotide sequence as set out in SEQ ID NO: 6 and the reverse primer consists of a nucleotide sequence as set out in SEQ ID NO: 7.
8. A method for detecting the presence of a strain of HRV-C in a sample comprising the steps of:
(a) extracting nucleic acid from the sample,
(b) amplifying said extracted nucleic acid, and
(c) determining the presence of one or more nucleic acid sequences specific for HRV-C, wherein the amplification step is, for instance, performed by an RT-PCR amplification by using at least one pair of primers as defined in claim 6 or 7.
9. The method according to claim 8, wherein the sample is selected from the group consisting of human nasal and oral samples and culture supernatants.
10. A kit for amplifying a strain of HRV-C in a sample comprising at least one pair of primers as defined in claim 6 or 7.
11. Use of a polynucleotide sequence as defined in claim 1 or fragments thereof in designing primers or probes for detecting HRV-C Rhinovirus in a sample.
12. An isolated protein encoded by a polynucleotide sequence as defined in claim 1.
13. An isolated protein encoded by a nucleic fragment, the nucleotide sequence of which is defined in claim 4.
14. An isolated protein comprising or consisting of an amino acid sequence identified as SEQ. ID. NO: 20.
15. A polypeptide characterized in that its amino acid sequence comprises or consists of at least 15 consecutive amino acids, preferably of at least 20 consecutive amino acids, advantageously of at least 30 consecutive amino acids of a protein as defined in anyone of claims 12, 13 and 14.
16. An antibody having specificity against an epitope of a protein as claimed in anyone of claims 12 to 14.
17. A method for detecting the presence of a strain of HRV-C in a sample comprising the steps of contacting the sample with a protein as defined in anyone of claims 12 to 14 or with a polypeptide as defined in claim 15 and detecting the presence of an immune complex formed between the protein or polypeptide and anti- HRV-C antibodies.
18. A method for detecting the presence of a strain of HRV-C in a sample comprising the steps of contacting the sample with at least one antibody as defined in claim 16 and detecting the presence of an immune complex of antibody/HRV-C protein.
19. The method according to claim 17, wherein the sample is a human sample selected from the group consisting of blood, plasma and serum.
20. The method according to claim 18, wherein the sample is selected from the group consisting of human nasal and oral samples and culture supernatants.
21. A kit for the diagnosis of a strain of HRV-C characterized in that it comprises at least one protein as defined in anyone of claims 12 to 14 or a polypeptide as defined in claim 15.
22. A kit for the diagnosis of a strain of HRV-C characterized in that it comprises at least one antibody as defined in claim 16.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09732607.8A EP2268800B1 (en) | 2008-04-17 | 2009-04-16 | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
CN200980113369.0A CN102007208B (en) | 2008-04-17 | 2009-04-16 | Human rhinovirus HRV-C and detection method thereof and test kit |
US12/936,004 US8709779B2 (en) | 2008-04-17 | 2009-04-16 | Newly identified human rhinovirus of HRV-C and methods and kits for detecting HRV-Cs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2008/000785 | 2008-04-17 | ||
PCT/CN2008/000785 WO2009127081A1 (en) | 2008-04-17 | 2008-04-17 | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009127154A1 true WO2009127154A1 (en) | 2009-10-22 |
Family
ID=41198755
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/000785 WO2009127081A1 (en) | 2008-04-17 | 2008-04-17 | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
PCT/CN2009/071310 WO2009127154A1 (en) | 2008-04-17 | 2009-04-16 | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/000785 WO2009127081A1 (en) | 2008-04-17 | 2008-04-17 | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
Country Status (4)
Country | Link |
---|---|
US (1) | US8709779B2 (en) |
EP (1) | EP2268800B1 (en) |
CN (1) | CN102007208B (en) |
WO (2) | WO2009127081A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009127081A1 (en) * | 2008-04-17 | 2009-10-22 | Biomerieux | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
WO2014140166A2 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Vaccine |
CN108504774B (en) * | 2018-02-26 | 2021-12-14 | 宁波海尔施基因科技有限公司 | Method for detecting rhinovirus typing and enterovirus |
CN113186343A (en) * | 2021-04-25 | 2021-07-30 | 济南国益生物科技有限公司 | Primer probe group for detecting human rhinovirus based on LFD-RMA method |
WO2023005805A1 (en) * | 2021-07-26 | 2023-02-02 | 北京万泰生物药业股份有限公司 | General affinity epitope polypeptide for human rhinovirus, and antibody and uses thereof |
CN115029477B (en) * | 2021-11-16 | 2023-06-16 | 江汉大学 | MNP (MNP-associated protein) marker locus of human rhinovirus, primer composition, kit and application of MNP marker locus |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63219384A (en) * | 1986-08-23 | 1988-09-13 | ベ−リンガ− インゲルハイム インタ−ナシヨナル ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Polypeptide of rhinovirus hrv89 and dna molecule for encoding the same |
JP2003093057A (en) * | 2001-09-26 | 2003-04-02 | Mitsubishi Kagaku Bio-Clinical Laboratories Inc | Method for identifying serotype or genotype by lineage analysis of rhinovirus |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006073436A2 (en) * | 2004-04-29 | 2006-07-13 | The Trustees Of Columbia University In The City Of New York | Mass tag pcr for multiplex diagnostics |
WO2008016594A1 (en) * | 2006-07-31 | 2008-02-07 | The Trustees Of Columbia University In The City Of New York | Picornavirus and uses thereof |
WO2009127081A1 (en) * | 2008-04-17 | 2009-10-22 | Biomerieux | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
US20100233677A1 (en) * | 2009-02-10 | 2010-09-16 | Liggett Stephen B | Full genome sequences of human rhinovirus strains |
US8821876B2 (en) * | 2009-05-26 | 2014-09-02 | Duke University | Methods of identifying infectious disease and assays for identifying infectious disease |
FI20095592A0 (en) * | 2009-05-28 | 2009-05-28 | Matti Waris | Differentiation of picornaviruses, nucleic acids therefor, use of same and bioassay procedures using the same |
-
2008
- 2008-04-17 WO PCT/CN2008/000785 patent/WO2009127081A1/en active Application Filing
-
2009
- 2009-04-16 CN CN200980113369.0A patent/CN102007208B/en active Active
- 2009-04-16 US US12/936,004 patent/US8709779B2/en active Active
- 2009-04-16 EP EP09732607.8A patent/EP2268800B1/en active Active
- 2009-04-16 WO PCT/CN2009/071310 patent/WO2009127154A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63219384A (en) * | 1986-08-23 | 1988-09-13 | ベ−リンガ− インゲルハイム インタ−ナシヨナル ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Polypeptide of rhinovirus hrv89 and dna molecule for encoding the same |
JP2003093057A (en) * | 2001-09-26 | 2003-04-02 | Mitsubishi Kagaku Bio-Clinical Laboratories Inc | Method for identifying serotype or genotype by lineage analysis of rhinovirus |
Non-Patent Citations (8)
Also Published As
Publication number | Publication date |
---|---|
EP2268800A1 (en) | 2011-01-05 |
CN102007208A (en) | 2011-04-06 |
EP2268800A4 (en) | 2012-08-15 |
US8709779B2 (en) | 2014-04-29 |
WO2009127081A1 (en) | 2009-10-22 |
CN102007208B (en) | 2016-06-01 |
US20110111391A1 (en) | 2011-05-12 |
EP2268800B1 (en) | 2017-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lau et al. | Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children | |
Pyrc et al. | Identification of new human coronaviruses | |
Kiang et al. | Assay for 5′ noncoding region analysis of all human rhinovirus prototype strains | |
Bok et al. | Evolutionary dynamics of GII. 4 noroviruses over a 34-year period | |
Lee et al. | High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses | |
Abdul-Rasool et al. | Understanding human coronavirus HCoV-NL63 | |
Harvala et al. | Epidemiology and clinical associations of human parechovirus respiratory infections | |
Pierangeli et al. | Detection and typing by molecular techniques of respiratory viruses in children hospitalized for acute respiratory infection in Rome, Italy | |
Bochkov et al. | Clinical and molecular features of human rhinovirus C | |
Abed et al. | Human parechovirus infections in Canada | |
Gerna et al. | Genetic variability of human coronavirus OC43‐, 229E‐, and NL63‐like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients | |
Dijkman et al. | Human bocavirus can be cultured in differentiated human airway epithelial cells | |
McIntyre et al. | Analysis of genetic diversity and sites of recombination in human rhinovirus species C | |
Chang et al. | A community‐derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005 | |
Tanaka et al. | Development and characterization of a genotype 4 hepatitis E virus cell culture system using a HE-JF5/15F strain recovered from a fulminant hepatitis patient | |
Li et al. | An outbreak of acute respiratory disease in China caused by human adenovirus type B55 in a physical training facility | |
US8709779B2 (en) | Newly identified human rhinovirus of HRV-C and methods and kits for detecting HRV-Cs | |
Geng et al. | A novel human coronavirus: Middle East respiratory syndrome human coronavirus | |
Nairn et al. | A study of enterovirus isolations in Glasgow from 1977 to 1997 | |
Xu et al. | Characterization of the nasopharyngeal viral microbiome from children with community‐acquired pneumonia but negative for Luminex xTAG respiratory viral panel assay detection | |
Farsani et al. | Identification of a new genotype of Torque Teno Mini virus | |
Wiyatno et al. | Detection and identification of coxsackievirus B3 from sera of an Indonesian patient with undifferentiated febrile illness | |
Ichiyama et al. | Determination of the 5′-terminal sequence of subgenomic RNA of hepatitis E virus strains in cultured cells | |
Linsuwanon et al. | The fecal virome of children with hand, foot, and mouth disease that tested PCR negative for pathogenic enteroviruses | |
Medici et al. | Broadly reactive nested reverse transcription-PCR using an internal RNA standard control for detection of noroviruses in stool samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980113369.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09732607 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009732607 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12936004 Country of ref document: US |